Lower riskDrug recall · FDA · Published February 10, 2026
LEO Pharma Adbry Injection Recall: Wool Fiber Contamination Risk
LEO Pharma recalls Adbry (tralokinumab-ldrm) injections due to wool fiber contamination in one unit from a specific lot. This may cause infection if injected. Affected units have NDC codes 50222-350-91 or 50222-350-02.
“LEO Pharma Adbry Injection Recall: Wool Fiber Contamination Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/31485-leo-pharma-adbry-injection-recall-wool-fiber-contamination-risk. Based on FDA recall #D-0339-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0339-2026%22&limit=1).
LEO Pharma Inc. recalled Adbry (tralokinumab-ldrm) injection nationwide due to a lack of sterility assurance caused by wool fiber particulate matter, the FDA announced on Feb. 10, 2026.
The recall addresses a lack of assurance of sterility because lab tests identified wool fiber particulate matter in one unit from the affected lots. The FDA stated this defect poses a risk to patients using the drug.
Context
GovInfoNow's records show LEO Pharma Inc. has two other recalls on file since Jan. 16, 2017, including labeling issues with Calcipotriene Cream and Taclonex Topical Suspension in January 2017. Other recent recalls of similar products include Lupin Liraglutide 18mg/3mL Injection (April 24, 2026), Baxter 0.9% Sodium Chloride Injection (Aug. 17, 2026), and B. Braun Medical Lactated Ringer's Injection (April 28, 2026).
How to tell if you have this one
Check the NDC code on the product label: 50222-350-91 for single-dose autoinjectors or 50222-350-02 for two-dose autoinjectors. The product is only available by prescription and is labeled as a sample not for sale.
Brand
LEO Pharma
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Label
Look for the NDC code 50222-350-91 or 50222-350-02 on the product label to identify affected units.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 22 days after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0339-2026 (February 10, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0339-2026 to see it in context.
Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.